Red cell distribution width as a predictor of prostate cancer progression

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 18, 2014, Pages 7781-7784

  Albayrak, Sebahattin ^a   Zengin, Kursad ^a   Tanik, Serhat ^a   Bakirtas, Hasan ^a   Imamoglu, Abdurrahim ^a   Gurdal, Mesut ^a  

^a BOZOK UNIVERSITY   (Turkey)

Author keywords

Progression; Prostate cancer; Red blood cell distribution width

Indexed keywords

TUMOR MARKER;

AGED; BLOOD; CANCER GRADING; CASE CONTROL STUDY; COMPARATIVE STUDY; DISEASE COURSE; FOLLOW UP; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MALE; MEAN CORPUSCULAR VOLUME; MIDDLE AGED; NEEDLE BIOPSY; PROGNOSIS; PROSTATIC NEOPLASMS;

AGED; BIOPSY, NEEDLE; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ERYTHROCYTE INDICES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 84908042874     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.18.7781     Document Type: Article

References (39)

1. Beer TM, Lalani AS, Lee S, et al (2008). C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer, 112, 2377-83.
2. Borre M, Nerstrom B, Overgaard J (1997). Erythrocyte sedimentation rate-a predictor of malignant potential in early prostate cancer. Acta Oncol, 36, 689-94.
3. Cakal B, Akoz AG, Ustundag Y, et al (2009). Red cell distribution width for assessment of activity of inflammatory bowel disease. Digestive Diseases and Sciences, 54, 842-7.
4. Celikbilek A, Zararsiz G, Atalay T, et al (2013). Red cell distribution width in migraine. Int J Lab Hematol, 35, 620-8.
5. Cheng I, Witte JS, Jacobsen SJ, et al (2010). Prostatitis, sexually transmitted diseases, and prostate cancer: the California men's health study. PLoS One, 5, 8736.
6. Cho H, Hur HW, Kim SW, et al (2009). Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother, 58, 15-23.
7. Cho H, Kim JH (2009). Multiplication of neutrophil and monocyte counts (MNM) as an easily obtainable tumour marker for cervical cancer. Biomarkers, 14, 161-70.
8. Cihan YB, Arslan A, Ergul MA (2013). Subtypes of white blood cells in patients with prostate cancer or benign prostatic hyperplasia and healthy individuals. Asian Pac J Cancer Prev, 14, 4779-83.
9. Dennis LK, Dawson DV (2002). Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology, 13, 72-9.
10. Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, et al (2010). C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet, 375, 132-40.
11. Felker GM, Allen LA, Pocock SJ, et al (2007). Red cell distribution width as a novel prognostic marker in heart failuredata from the charm program and the duke databank. J Am College Cardiol, 50, 40-7.
12. Ferronika P, Triningsih FX, Ghozali A, et al (2012). p63 cytoplasmic aberrance is associated with high prostate cancer stem cell expression. Asian Pac J Cancer Prev, 13, 1943-8.
13. Fujita K, Imamura R, Tanigawa G, et al (2012). Low serum neutrophil count predicts a positive prostate biopsy. Prostate Cancer Prostatic Dis, 15, 386-90.
14. Godsland IF, North BV, Johnston DG (2011). Simple indices of inflammation as predictors of death from cancer or cardiovascular disease in a prospective cohort after two decades of follow-up. Qjm-an Int J Med, 104, 387-94.
15. Henry-Amar M, Friedman S, Hayat M, et al (1991). Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group. Ann Intern Med, 114, 361-5.
16. Japanese Urological Association (2010). Committee for Establishment of the Guidelines on Screening for Prostate Cancer1; Updated Japanese urological association guidelines on prostate-specific antigen-based screening for prostate cancer in 2010. Int J Urol, 17, 830-8.
17. Kazma R, Mefford JA, Cheng I, et al (2012). Association of the Innate Immunity and Inflammation Pathway with Advanced Prostate Cancer Risk. Plos One, 7.
18. Klink JC, Banez LL, Gerber L, et al (2013). Intratumoral inflammation is associated with more aggressive prostate cancer. World J Urol, 31, 1497-503.
19. Kundu JK, Surh YJ (2008). Inflammation: gearing the journey to cancer. Mutat Res, 659, 15-30.
20. Leitzmann MF, Rohrmann S (2012). Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol, 4, 1-11.
21. Lippi G, Targher G, Montagnana M, et al (2009). Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. Arch Pathol Laboratory Med, 133, 628-32.
22. Maruyama S, Hirayama C, Yamamoto S, et al (2001). Red blood cell status in alcoholic and non-alcoholic liver disease. J Laboratory Clin Med, 138, 332-7.
23. McArdle PA, Qayyum T, McMillan DC (2010). Systemic inflammatory response and survival in patients with localised prostate cancer: 10-year follow-up. Urol Int, 84, 430-5.
24. Mengus C, Le Magnen C, Trella E, et al (2011). Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. J Transl Med, 9, 162.
25. Mitchell RMS, Robinson TJ (2002). Monitoring dietary compliance in coeliac disease using red cell distribution width. Int J Clin Practice, 56, 249-50.
26. Nelson JE, Harris RE (2000). Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): Results of a case-control study. Oncology Reports, 7, 169-70.
27. Nonomura N, Takayama H, Kawashima A, et al (2010). Decreased infiltration of macrophage scavenger receptor-positive cells in initial negative biopsy specimens is correlated with positive repeat biopsies of the prostate. Cancer Sci, 101, 1570-3.
28. Odom BD, Mir M, Hughes S, et al (2013). Active surveillance for low-risk prostate cancer in African American men: A multi-institutional experience. Urology, 83, 364-8.
29. Ozkalemkas F, Ali R, Ozkocaman V, et al (2005). The bone marrow aspirate and biopsy in the diagnosis of unsuspected nonhematologic malignancy: A clinical study of 19 cases. Bmc Cancer, 5, 144.
30. Patel KV, Ferrucci L, Ershler WB, et al (2009). Red blood cell distribution width and the risk of death in middle-aged and older adults. Arch Intern Med, 169, 515-23.
31. Patel KV, Semba RD, Ferrucci L, et al (2010). Red cell distribution width and mortality in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci, 65, 258-65.
32. Perlstein TS, Weuve J, Pfeffer MA, et al (2009). Red blood cell distribution width and mortality risk in a community-based prospective cohort. Arch Intern Med, 169, 588-94.
33. Sfanos KS, De Marzo AM (2012). Prostate cancer and inflammation: the evidence. Histopathol, 60, 199-215.
34. Shah R, Mucci NR, Amin A, et al (2001). Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? Am J Pathol, 158, 1767-73.
35. Siegel R, DeSantis C, Virgo K, et al (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin, 62, 220-41.
36. Sooriakumaran P, Srivastava A, Christos P, et al (2012). Predictive models for worsening prognosis in potential candidates for active surveillance of presumed low-risk prostate cancer. Int Urol Nephrol, 44, 459-70.
37. Spell DW, Jones DV, Harper WF, et al (2004). The value of a complete blood count in predicting cancer of the colon. Cancer Detection Prev, 28, 37-42.
38. Walsh SR, Cook EJ, Goulder F, et al (2005). Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol, 91, 181-4.
39. Wang J, Yang J, Zou Y, et al (2013). Orphan nuclear receptor nurr1 as a potential novel marker for progression in human prostate cancer. Asian Pac J Cancer Prev, 14, 2023-8.